Operating income before deduction of amortization: Alkermes PLC (ALKS)

Brandmark of Alkermes (ALKS)

Patent frictions and declining royalties are putting pressure on Alkermes plc (ALKS), yet the net operating income before depreciation reflects the business's resilience. The value of 174.90 determines this parameter level. Stability is sustained by a strong reputation in treating neuroses and the protection of unique drug delivery methods, which require colossal expenditures for certification and research.

Alkermes plc (ALKS) Operating profit EBITDA: for the period 11/23/2025 - 11/10/2026

Summary analytical data breakdowns for Alkermes (ALKS)

- share price and consensus valuation forecast:
Quote Chart Alkermes Corp|ALKS - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Alkermes|ALKS - Real Price to Acquire Entire Company
- balance sheet equity data:
Net Asset Value per Share Alkermes|ALKS - Book Capitalization|Market Cap to Net Assets Ratio alkermes.com|ALKS - Company Total Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Alkermes plc|ALKS - Long-Term Debt to Equity|Current Liabilities to Capital Alkermes PLC|ALKS - Company Aggregate Debts|Debts to Book Capitalization Alkermes|ALKS - Company Long-Term Debt|Company Short-Term Debt Alkermes|Quick Ratio alkermes.com
- earnings and market multiples details:
ALKS - Net Profit|Expected Net Profit Alkermes plc|ALKS - Price to Earnings Ratio|Future Price to Earnings Multiple alkermes.com|ALKS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Alkermes|ALKS - Operating profit EBITDA|Net earnings per one share for the last twelve months Alkermes|ALKS - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months alkermes.com|ALKS - Net earnings per share growth this year|Expected earnings per share trend next year Alkermes plc
Summary company analytics:ALKS (Alkermes Corp)
Brand item of Alkermes plc

Investors are verifying the financial stability of Alkermes plc (ALKS) through cash flow analysis, which confirms the business's ability to generate real liquidity. The EBITDA_Co trend on this chart reflects the net funds derived from the sale of psychotropic drugs, where the efficiency of specialized logistics and route control converts directly into operating profit, signaling either business growth or the risk of asset overheating.

Competitors of Alkermes plc (ALKS)

AVDL (Avadel Corp) - Profit before deduction of interest, taxes, depreciation and amortization|ATAI - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization ghres.com GHRS|MNMD (MindMed) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization COMPASS Pathways PLC (CMPS)|LBRX (LB Pharma) - Operating profit EBITDA|Operating profit before deduction of amortization Bright Minds Corp (DRUG)|Operating profit EBITDA VNDA|CYBN (cybin.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Alto Neuroscience ANRO|NRx Pharmaceuticals Inc. (NRXP) - Profit before interest, taxes and amortization|Cingulate Corp - Operating profit EBITDA|SILO - Operating profit EBITDA|chinapharmaholdings.com (CPHI) - Profit before payment of interest, taxes and amortization|CMND (clearmindmedicine.com) - Profit before payment of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Psyence Biomedical|Operating profit EBITDA SciSparc Ltd.|Operating profit EBITDA SEEL|VRPX - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Karuna Therapeutics KRTX